Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
32.29 USD | -3.96% | -7.05% | +59.46% |
Business Summary
Number of employees: 244
Sales per Business
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Pharmaceutical Products
100.0
%
| 26 | 100.0 % | 17 | 100.0 % | -32.42% |
Sales per region
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
United States
100.0
%
| 26 | 100.0 % | 17 | 100.0 % | -32.42% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Bobak Azamian
CEO | Chief Executive Officer | 46 | 16-12-31 |
Jeffrey Farrow
DFI | Director of Finance/CFO | 62 | 23-04-23 |
Sesha Neervannan
COO | Chief Operating Officer | 56 | 20-07-15 |
David Nakasone
IRC | Investor Relations Contact | - | - |
Mark Luz
PRN | Corporate Officer/Principal | - | - |
Scott Youmans
SAM | Sales & Marketing | 53 | 22-02-28 |
Bryan Wahl
LAW | General Counsel | 46 | 21-01-18 |
Maáza Martin
SAM | Sales & Marketing | - | - |
Dianne Whitfield
HRO | Human Resources Officer | 47 | 21-01-06 |
Aziz Mottiwala
PRN | Corporate Officer/Principal | 46 | 20-06-30 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Bill Link
BRD | Director/Board Member | 78 | 16-12-31 |
Wendy Yarno
BRD | Director/Board Member | 68 | 20-11-18 |
Director/Board Member | 69 | 19-11-30 | |
Rosemary Crane
BRD | Director/Board Member | 64 | 21-08-10 |
Bobak Azamian
CEO | Chief Executive Officer | 46 | 16-12-31 |
Andrew Goldberg
BRD | Director/Board Member | 42 | 20-07-31 |
Scott Morrison
BRD | Director/Board Member | 66 | 22-10-05 |
Director/Board Member | 45 | 22-01-03 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 37,781,693 | 33,214,163 ( 87.91 %) | 0 | 87.91 % |
Company contact information
Sector
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+59.46% | 1.22B | |
+43.64% | 754B | |
+40.25% | 630B | |
-6.58% | 352B | |
+19.72% | 331B | |
+8.78% | 298B | |
+18.52% | 250B | |
+12.36% | 217B | |
-0.29% | 216B | |
+6.13% | 164B |
- Stock Market
- Equities
- TARS Stock
- Company Tarsus Pharmaceuticals, Inc.